This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Web-Based Follow-Up Using Cellular Phone in Type 1 Diabetic Patients Under Insulin Pump Therapy : The PumpNet Study

This study has been completed.
Information provided by:
University Hospital, Grenoble Identifier:
First received: May 10, 2006
Last updated: July 4, 2006
Last verified: July 2006
The purpose of this study is to determine if telecare using modern telecommunication devices can improve the metabolic control and the quality of life of type 1 diabetic patients.

Condition Intervention Phase
Type 1 Diabetes Mellitus Device: Telemonitoring of glucose values using GlucoNet device Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Surveillance Des données De l’Autosurveillance glycémique Via Internet Et Le réseau téléphonique GSM Chez Le diabétique De Type 1 Sous Traitement Insulinique Par Pompe Externe : Etude Prospective randomisée PumpNet.

Resource links provided by NLM:

Further study details as provided by University Hospital, Grenoble:

Primary Outcome Measures:
  • Glycated hemoglobin HbA1c
  • monthly mean capillary blood glucose value
  • blood glucose variability index (MAGE Index and LBGI index)
  • quality of life score (DQOL score)
  • frequency of hypoglycemic episodes (<70 mg/dl)

Estimated Enrollment: 40
Study Start Date: April 2003
Estimated Study Completion Date: September 2004
Detailed Description:
We aim at comparing conventional follow-up of type 1 diabetic patients treated with continuous subcutaneous insulin infusion (CSII) (face-to-face visits) with an intensive coaching using the Web and the cellular phone network for data transmission and Short Message Service (SMS). This telecommunication device is called GlucoNet. The specific objectives are to measure the efficiency of GlucoNet in improving metabolic control, reducing health care costs and improving the quality of life of patients.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 diabetes mellitus
  • Age ≥ 18
  • HbA1c between 7.5 and 10%
  • Treated with continuous subcutaneous insulin infusion for a minimum of 3 months

Exclusion Criteria:

  • Unstabilized diabetic microangiopathy
  • Ongoing pregnancy or planned pregnancy
  • Unwilling to perform a minimum of 4 capillary blood tests per day
  • Unable to use the GlucoNet device
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00324584

University Hospital, Department of Endocrinology
Grenoble, France, 38043
University Hospital, Department of Endocrinology
Toulouse, France, 31000
Sponsors and Collaborators
University Hospital, Grenoble
Principal Investigator: Pierre Y Benhamou, MD, PhD Universty Hospital, Grenoble, France
Study Director: Helene Hanaire, MD, PhD University Hospital, Toulouse, France
Study Director: Serge Halimi, MD University Hospital, Grenoble, France
Study Director: Jean L Bosson, MD, PhD CIC-INSERM
  More Information Identifier: NCT00324584     History of Changes
Other Study ID Numbers: DCIC 03 01
Study First Received: May 10, 2006
Last Updated: July 4, 2006

Keywords provided by University Hospital, Grenoble:
type 1 diabetes mellitus
insulin pump therapy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases processed this record on August 22, 2017